NCT05268601View on ClinicalTrials.gov

COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

CompletedOBSERVATIONAL
Enrollment

251

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

December 22, 2023

Study Completion Date

December 22, 2023

Conditions
COVID-19
Interventions
DRUG

Bamlanivimab

Administration of monoclonal antibody against SARS-CoV-2

DRUG

Bamlanivimab and Etesevimab Drug Combination

Combined administration of monoclonal antibodies against SARS-CoV-2

DRUG

Casirivimab and Imdevimab Drug Combination

Combined administration of monoclonal antibodies against SARS-CoV-2

DRUG

Sotrovimab

Administration of monoclonal antibody against SARS-CoV-2

Trial Locations (1)

20900

Asst-Monza Ospedale San Gerardo, Monza

All Listed Sponsors
lead

University of Milano Bicocca

OTHER

NCT05268601 - COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 | Biotech Hunter | Biotech Hunter